{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:17:21Z","timestamp":1788513441082,"version":"build-2803163510"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005968","name":"Leukemia Research Foundation","doi-asserted-by":"publisher","award":["Hollis Brownstein Research Grant"],"award-info":[{"award-number":["Hollis Brownstein Research Grant"]}],"id":[{"id":"10.13039\/100005968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["MFAG 2019 Id23321 plus Bridge grant"],"award-info":[{"award-number":["MFAG 2019 Id23321 plus Bridge grant"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["ERC Consolidator grant 101003186 ReviveSTEM"],"award-info":[{"award-number":["ERC Consolidator grant 101003186 ReviveSTEM"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["Advanced research grant 2019"],"award-info":[{"award-number":["Advanced research grant 2019"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Chemotherapy resistance and disease relapse are major determinants of treatment failure in acute myeloid leukemia (AML). Therapy-induced senescence (TIS) is one outcome of chemotherapy, but its immunological consequences in AML remain unclear. Here we show that ex vivo chemotherapy induces senescence in a subset of therapy-na\u00efve AML samples. TIS is marked by elevated interferon signaling, upregulation of human leukocyte antigen (HLA) class I and II molecules, and increased presentation of leukemia- and senescence-associated peptides, conferring AML cells antigen-presenting cell-like features. These changes enhance autologous CD4\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    \u2009T cell responses against AML, both ex vivo and in patient-derived xenograft models. TIS also restores AML sensitivity to immune checkpoint blockade therapy. Mechanistically, we identify reduced Polycomb Repressive Complex 2 (PRC2) activity as central to TIS induction and its immunogenicity. PRC2 inhibition reactivates senescence-related genes and HLA expression in non-senescent AML cells, enabling T cell activation. These findings uncover a senescence-driven immune mechanism with potential to improve therapy outcomes in AML.\n                  <\/jats:p>","DOI":"10.1038\/s41467-026-76853-1","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:03:02Z","timestamp":1788512582000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapy induced senescence promotes immunogenicity in acute myeloid Leukemia through reduced EZH2 activity"],"prefix":"10.1038","volume":"17","author":[{"given":"Diego","family":"Gilioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8272-7902","authenticated-orcid":false,"given":"Simona","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2298-4413","authenticated-orcid":false,"given":"Teresa","family":"Tavella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Volpari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1012-888X","authenticated-orcid":false,"given":"Antonella","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1010-0975","authenticated-orcid":false,"given":"Martin","family":"Sch\u00f6nlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kety","family":"Giannetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6200-2868","authenticated-orcid":false,"given":"Edoardo","family":"Carsana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0622-6118","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Gualandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Noberini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Brombin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4012-4310","authenticated-orcid":false,"given":"Sara","family":"Feola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4265-5411","authenticated-orcid":false,"given":"Yvonne","family":"Giannoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui M. M.","family":"Branca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janne","family":"Lehti\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-1301","authenticated-orcid":false,"given":"Tiina M.","family":"Sikanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7828-8663","authenticated-orcid":false,"given":"Markus","family":"Haapala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Passerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Andrisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Farina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Zangari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8670-2649","authenticated-orcid":false,"given":"Anastasia","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9087-1293","authenticated-orcid":false,"given":"Lucrezia","family":"della Volpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Barcella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Beretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Mario","family":"Aletti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7015-4839","authenticated-orcid":false,"given":"Matteo Giovanni","family":"Carrabba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3517-9683","authenticated-orcid":false,"given":"Silvia","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0772-1674","authenticated-orcid":false,"given":"Chiara","family":"Bonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3587-3680","authenticated-orcid":false,"given":"Ivan","family":"Merelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4901-3796","authenticated-orcid":false,"given":"Vincenzo","family":"Cerullo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3556-1265","authenticated-orcid":false,"given":"Tiziana","family":"Bonaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4247-3175","authenticated-orcid":false,"given":"Luca","family":"Vago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4731-2226","authenticated-orcid":false,"given":"Clemens A.","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0639-8238","authenticated-orcid":false,"given":"Raffaella","family":"Di Micco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"76853_CR1","first-page":"67","volume":"6","author":"PH Wiernik","year":"1992","unstructured":"Wiernik, P. H. & Dutcher, J. P. Clinical importance of anthracyclines in the treatment of acute myeloid leukemia. Leukemia 6, 67\u201369 (1992).","journal-title":"Leukemia"},{"key":"76853_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1080\/10428194.2018.1504937","volume":"60","author":"CM McMahon","year":"2019","unstructured":"McMahon, C. M. & Perl, A. E. Management of primary refractory acute myeloid leukemia in the era of targeted therapies. Leuk. Lymphoma 60, 583\u2013597 (2019).","journal-title":"Leuk. Lymphoma"},{"key":"76853_CR3","doi-asserted-by":"publisher","unstructured":"T. Marchand, S. Pinho, Leukemic stem cells: from Leukemic niche biology to treatment opportunities. Front. Immunol. 12, https:\/\/doi.org\/10.3389\/fimmu.2021.775128 (2021).","DOI":"10.3389\/fimmu.2021.775128"},{"key":"76853_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41580-020-00314-w","volume":"22","author":"R Di Micco","year":"2021","unstructured":"Di Micco, R., Krizhanovsky, V., Baker, D. & d\u2019Adda di Fagagna, F. Cellular senescence in ageing: from mechanisms to therapeutic opportunities. Nat. Rev. Mol. Cell Biol. 22, 75\u201395 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"76853_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood.V118.21.107.107","volume":"118","author":"J D\u00f6rr","year":"2011","unstructured":"D\u00f6rr, J. et al. Therapy-inducible senescence activates both innate and adaptive immune mechanisms that control Lymphoma growth in vivo. Blood 118, 107 (2011).","journal-title":"Blood"},{"key":"76853_CR6","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.1002\/1878-0261.13268","volume":"16","author":"M Takasugi","year":"2022","unstructured":"Takasugi, M., Yoshida, Y. & Ohtani, N. Cellular senescence and the tumour microenvironment. Mol. Oncol. 16, 3333\u20133351 (2022).","journal-title":"Mol. Oncol."},{"key":"76853_CR7","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41568-022-00450-9","volume":"22","author":"L Wang","year":"2022","unstructured":"Wang, L., Lankhorst, L. & Bernards, R. Exploiting senescence for the treatment of cancer. Nat. Rev. Cancer 22, 340\u2013355 (2022).","journal-title":"Nat. Rev. Cancer"},{"key":"76853_CR8","doi-asserted-by":"crossref","unstructured":"Lee, S. & Schmitt, C. A. The dynamic nature of senescence in cancer. Nat. Cell Biol. 21, 94\u2013101 (2019).","DOI":"10.1038\/s41556-018-0249-2"},{"key":"76853_CR9","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","volume":"75","author":"J Campisi","year":"2013","unstructured":"Campisi, J. Aging, cellular senescence, and cancer. Annu. Rev. Physiol. 75, 685\u2013705 (2013).","journal-title":"Annu. Rev. Physiol."},{"key":"76853_CR10","doi-asserted-by":"publisher","first-page":"2463","DOI":"10.1101\/gad.1971610","volume":"24","author":"T Kuilman","year":"2010","unstructured":"Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of senescence. Genes Dev. 24, 2463\u20132479 (2010).","journal-title":"Genes Dev."},{"key":"76853_CR11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2117754119","volume":"119","author":"SV Paffenholz","year":"2022","unstructured":"Paffenholz, S. V. et al. Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer. Proc. Natl. Acad. Sci. USA 119, e2117754119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76853_CR12","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","volume":"7","author":"M Demaria","year":"2017","unstructured":"Demaria, M. et al. Cellular senescence promotes adverse effects of chemotherapy and cancer relapse. Cancer Discov. 7, 165\u2013176 (2017).","journal-title":"Cancer Discov."},{"key":"76853_CR13","doi-asserted-by":"crossref","unstructured":"Duy, C. et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 11, 1542\u20131561 (2021).","DOI":"10.1158\/2159-8290.CD-20-1375"},{"key":"76853_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nature25167","volume":"553","author":"M Milanovic","year":"2018","unstructured":"Milanovic, M. et al. Senescence-associated reprogramming promotes cancer stemness. Nature 553, 96\u2013100 (2018).","journal-title":"Nature"},{"key":"76853_CR15","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1038\/s43018-022-00466-y","volume":"3","author":"A Shahbandi","year":"2022","unstructured":"Shahbandi, A. et al. Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80. Nat. Cancer 3, 1513\u20131533 (2022).","journal-title":"Nat. Cancer"},{"key":"76853_CR16","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/s43018-023-00712-x","volume":"5","author":"S Chaib","year":"2024","unstructured":"Chaib, S. et al. The efficacy of chemotherapy is limited by intratumoral senescent cells expressing PD-L2. Nat. Cancer 5, 448\u2013462 (2024).","journal-title":"Nat. Cancer"},{"key":"76853_CR17","doi-asserted-by":"crossref","unstructured":"Wen, X. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656\u2013660 (2007).","DOI":"10.1038\/nature05529"},{"key":"76853_CR18","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nature10599","volume":"479","author":"T-W Kang","year":"2011","unstructured":"Kang, T.-W. et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479, 547\u2013551 (2011).","journal-title":"Nature"},{"key":"76853_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/nature13638","volume":"515","author":"D Di Mitri","year":"2014","unstructured":"Di Mitri, D. et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 515, 134\u2013137 (2014).","journal-title":"Nature"},{"key":"76853_CR20","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1210\/en.2016-1886","volume":"158","author":"M Egashira","year":"2017","unstructured":"Egashira, M. et al. F4\/80+ Macrophages contribute to clearance of senescent cells in the mouse postpartum uterus. Endocrinology 158, 2344\u20132353 (2017).","journal-title":"Endocrinology"},{"key":"76853_CR21","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1182\/blood-2008-08-173914","volume":"113","author":"A Soriani","year":"2009","unstructured":"Soriani, A. et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 113, 3503\u20133511 (2009).","journal-title":"Blood"},{"key":"76853_CR22","first-page":"938","volume":"2","author":"S Arora","year":"2021","unstructured":"Arora, S. et al. Invariant natural killer T cells coordinate removal of senescent cells. Med N. Y. N 2, 938\u2013950 (2021).","journal-title":"Med N. Y. N"},{"key":"76853_CR23","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1182\/blood.2020005244","volume":"137","author":"M Reimann","year":"2021","unstructured":"Reimann, M. et al. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood 137, 2785\u20132799 (2021).","journal-title":"Blood"},{"key":"76853_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57429-x","volume":"16","author":"D Belenki","year":"2025","unstructured":"Belenki, D. et al. Schmitt, Senescence-associated lineage-aberrant plasticity evokes T-cell-mediated tumor control. Nat. Commun. 16, 3079 (2025).","journal-title":"Nat. Commun."},{"key":"76853_CR25","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1158\/2159-8290.CD-22-0523","volume":"13","author":"I Marin","year":"2023","unstructured":"Marin, I. et al. Cellular senescence is immunogenic and promotes antitumor immunity. Cancer Discov. 13, 410\u2013431 (2023).","journal-title":"Cancer Discov."},{"key":"76853_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1158\/2159-8290.CD-22-0528","volume":"13","author":"H-A Chen","year":"2023","unstructured":"Chen, H.-A. et al. Senescence rewires microenvironment sensing to facilitate antitumor immunity. Cancer Discov. 13, 432\u2013453 (2023).","journal-title":"Cancer Discov."},{"key":"76853_CR27","doi-asserted-by":"crossref","unstructured":"Jan, D. et al. Therapy-inducible senescence activates both innate and adaptive immune mechanisms that control lymphoma growth in vivo. Blood 118, 107 (2011).","DOI":"10.1182\/blood.V118.21.107.107"},{"key":"76853_CR28","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1146\/annurev-pathol-121808-102144","volume":"5","author":"J-P Copp\u00e9","year":"2010","unstructured":"Copp\u00e9, J.-P., Desprez, P.-Y., Krtolica, A. & Campisi, J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu. Rev. Pathol. 5, 99\u2013118 (2010).","journal-title":"Annu. Rev. Pathol."},{"key":"76853_CR29","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1038\/onc.2008.213","volume":"27","author":"AL Fridman","year":"2008","unstructured":"Fridman, A. L. & Tainsky, M. A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27, 5975\u20135987 (2008).","journal-title":"Oncogene"},{"key":"76853_CR30","doi-asserted-by":"publisher","first-page":"12489","DOI":"10.3390\/ijms222212489","volume":"22","author":"H Lee","year":"2021","unstructured":"Lee, H., Hong, Y. & Kim, M. Structural and functional changes and possible molecular mechanisms in aged skin. Int. J. Mol. Sci. 22, 12489 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"76853_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ccr.2013.06.005","volume":"24","author":"A Pribluda","year":"2013","unstructured":"Pribluda, A. et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24, 242\u2013256 (2013).","journal-title":"Cancer Cell"},{"key":"76853_CR32","doi-asserted-by":"publisher","first-page":"3927","DOI":"10.4161\/15384101.2014.973327","volume":"13","author":"M Purcell","year":"2014","unstructured":"Purcell, M., Kruger, A. & Tainsky, M. A. Gene expression profiling of replicative and induced senescence. Cell Cycle Georget. Tex 13, 3927\u20133937 (2014).","journal-title":"Cell Cycle Georget. Tex"},{"key":"76853_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32552-1","volume":"13","author":"D Saul","year":"2022","unstructured":"Saul, D. et al. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. Nat. Commun. 13, 4827 (2022).","journal-title":"Nat. Commun."},{"key":"76853_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17467-z","volume":"11","author":"K Schleich","year":"2020","unstructured":"Schleich, K. et al. H3K9me3-mediated epigenetic regulation of senescence in mice predicts outcome of lymphoma patients. Nat. Commun. 11, 3651 (2020).","journal-title":"Nat. Commun."},{"key":"76853_CR35","doi-asserted-by":"publisher","first-page":"109441","DOI":"10.1016\/j.celrep.2021.109441","volume":"36","author":"F Jochems","year":"2021","unstructured":"Jochems, F. et al. The cancer SENESCopedia: A delineation of cancer cell senescence. Cell Rep. 36, 109441 (2021).","journal-title":"Cell Rep."},{"key":"76853_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36969-0","volume":"14","author":"MM Naldini","year":"2023","unstructured":"Naldini, M. M. et al. Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia. Nat. Commun. 14, 1285 (2023).","journal-title":"Nat. Commun."},{"key":"76853_CR37","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen, P. et al. Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell 176, 1265\u20131281 (2019).","journal-title":"Cell"},{"key":"76853_CR38","doi-asserted-by":"crossref","unstructured":"Zhang, D., Li, Y., Liu, T., Liu, X. & Zhang, J. Neutrophil-related genes predict prognosis and contribute to immunosuppression in acute myeloid Leukemia. Blood Lymphat Cancer 15, 115\u2013132 (2025).","DOI":"10.2147\/BLCTT.S529074"},{"key":"76853_CR39","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.stem.2025.04.012","volume":"32","author":"M Sirenko","year":"2025","unstructured":"Sirenko, M. et al. Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia. Cell Stem Cell 32, 1102\u20131121 (2025).","journal-title":"Cell Stem Cell"},{"key":"76853_CR40","doi-asserted-by":"publisher","first-page":"e002071","DOI":"10.1136\/jitc-2020-002071","volume":"9","author":"A Marcu","year":"2021","unstructured":"Marcu, A. et al. HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. J. Immunother. Cancer 9, e002071 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"76853_CR41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1182\/blood-2018-07-866830","volume":"133","author":"T Bilich","year":"2019","unstructured":"Bilich, T. et al. The HLA ligandome landscape of chronic myeloid leukemia delineates novel T-cell epitopes for immunotherapy. Blood 133, 550\u2013565 (2019).","journal-title":"Blood"},{"key":"76853_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-020-01990-9","volume":"21","author":"RA Avelar","year":"2020","unstructured":"Avelar, R. A. et al. A multidimensional systems biology analysis of cellular senescence in aging and disease. Genome Biol. 21, 91 (2020).","journal-title":"Genome Biol."},{"key":"76853_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57047-7","volume":"16","author":"MA Sanborn","year":"2025","unstructured":"Sanborn, M. A., Wang, X., Gao, S., Dai, Y. & Rehman, J. Unveiling the cell-type-specific landscape of cellular senescence through single-cell transcriptomics using SenePy. Nat. Commun. 16, 1884 (2025).","journal-title":"Nat. Commun."},{"key":"76853_CR44","doi-asserted-by":"publisher","DOI":"10.1126\/science.aah4573","volume":"356","author":"A-C Villani","year":"2017","unstructured":"Villani, A.-C. et al. Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors. Science 356, eaah4573 (2017).","journal-title":"Science"},{"key":"76853_CR45","doi-asserted-by":"crossref","unstructured":"Keskinen, P., Ronni, T., Matikainen, S., Lehtonen, A. & Julkunen, I. Regulation of HLA class I and II expression by interferons and influenza A virus in human peripheral blood mononuclear cells. 91, 421\u2013429 (1997).","DOI":"10.1046\/j.1365-2567.1997.00258.x"},{"key":"76853_CR46","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.omtm.2023.08.020","volume":"30","author":"C Asperti","year":"2023","unstructured":"Asperti, C. et al. Scalable GMP-compliant gene correction of CD4+ T cells with IDLV template functionally validated in vitro and in vivo. Mol. Ther. Methods Clin. Dev. 30, 546\u2013557 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"76853_CR47","unstructured":"U.S. Food and Drug Administration. FDA granted accelerated approval to tazemetostat for follicular lymphoma. FDA https:\/\/www.fda.gov\/drugs\/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma (2020)."},{"key":"76853_CR48","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1016\/j.cub.2017.07.033","volume":"27","author":"A Hernandez-Segura","year":"2017","unstructured":"Hernandez-Segura, A. et al. Unmasking transcriptional heterogeneity in senescent cells. Curr. Biol. 27, 2652\u20132660.e4 (2017).","journal-title":"Curr. Biol."},{"key":"76853_CR49","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.immuni.2021.11.015","volume":"54","author":"DY Oh","year":"2021","unstructured":"Oh, D. Y. & Fong, L. Cytotoxic CD4+ T cells in cancer: Expanding the immune effector toolbox. Immunity 54, 2701\u20132711 (2021).","journal-title":"Immunity"},{"key":"76853_CR50","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","volume":"379","author":"MJ Christopher","year":"2018","unstructured":"Christopher, M. J. et al. Immune escape of relapsed AML cells after allogeneic transplantation. N. Engl. J. Med. 379, 2330\u20132341 (2018).","journal-title":"N. Engl. J. Med."},{"key":"76853_CR51","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603\u2013611 (2019).","journal-title":"Nat. Med."},{"key":"76853_CR52","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/j.cell.2023.02.033","volume":"186","author":"T Hasegawa","year":"2023","unstructured":"Hasegawa, T. et al. Cytotoxic CD4+ T cells eliminate senescent cells by targeting cytomegalovirus antigen. Cell 186, 1417\u20131431 (2023).","journal-title":"Cell"},{"key":"76853_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","volume":"12","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu, J. et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci. Transl. Med. 12, eaaz0463 (2020).","journal-title":"Sci. Transl. Med."},{"key":"76853_CR54","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2116427118","volume":"118","author":"F Ferraro","year":"2021","unstructured":"Ferraro, F. et al. Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. Proc. Natl. Acad. Sci. USA 118, e2116427118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"76853_CR55","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/2159-8290.CD-21-0980","volume":"12","author":"V Gambacorta","year":"2022","unstructured":"Gambacorta, V. et al. Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract Leukemia immune escape and relapse. Cancer Discov. 12, 1449\u20131461 (2022).","journal-title":"Cancer Discov."},{"key":"76853_CR56","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","volume":"9","author":"D Ennishi","year":"2019","unstructured":"Ennishi, D. et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 9, 546\u2013563 (2019).","journal-title":"Cancer Discov."},{"key":"76853_CR57","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s43018-021-00185-w","volume":"2","author":"KL Morel","year":"2021","unstructured":"Morel, K. L. et al. EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer. Nat. Cancer 2, 444\u2013456 (2021).","journal-title":"Nat. Cancer"},{"key":"76853_CR58","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.immuni.2020.11.002","volume":"54","author":"D Dersh","year":"2021","unstructured":"Dersh, D. et al. Genome-wide screens identify lineage- and tumor-specific genes modulating MHC-I- and MHC-II-restricted immunosurveillance of human lymphomas. Immunity 54, 116\u2013131 (2021).","journal-title":"Immunity"},{"key":"76853_CR59","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s43018-023-00553-8","volume":"4","author":"L Chibaya","year":"2023","unstructured":"Chibaya, L. et al. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance. Nat. Cancer 4, 872\u2013892 (2023).","journal-title":"Nat. Cancer"},{"key":"76853_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1101\/gad.415507","volume":"21","author":"AP Bracken","year":"2007","unstructured":"Bracken, A. P. et al. The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev. 21, 525\u2013530 (2007).","journal-title":"Genes Dev."},{"key":"76853_CR61","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1016\/j.celrep.2018.03.002","volume":"22","author":"T Ito","year":"2018","unstructured":"Ito, T., Teo, Y. V., Evans, S. A., Neretti, N. & Sedivy, J. M. Regulation of cellular senescence by polycomb chromatin modifiers through distinct DNA damage- and histone methylation-dependent pathways. Cell Rep. 22, 3480\u20133492 (2018).","journal-title":"Cell Rep."},{"key":"76853_CR62","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ccell.2019.08.008","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385\u2013401 (2019).","journal-title":"Cancer Cell"},{"key":"76853_CR63","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ccell.2024.11.006","volume":"43","author":"Y Isshiki","year":"2025","unstructured":"Isshiki, Y. et al. EZH2 inhibition enhances T cell immunotherapies by inducing lymphoma immunogenicity and improving T cell function. Cancer Cell 43, 49\u201368 (2025).","journal-title":"Cancer Cell"},{"key":"76853_CR64","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/s41573-021-00345-8","volume":"21","author":"AJ Korman","year":"2022","unstructured":"Korman, A. J., Garrett-Thomson, S. C. & Lonberg, N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat. Rev. Drug Discov. 21, 509\u2013528 (2022).","journal-title":"Nat. Rev. Drug Discov."},{"key":"76853_CR65","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct. Target. Ther. 8, 320 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"76853_CR66","doi-asserted-by":"crossref","unstructured":"Chen, Y., Wang, J., Zhang, F. & Liu, P. A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges. Front. Pharmacol. 14, 1151032 (2023).","DOI":"10.3389\/fphar.2023.1151032"},{"key":"76853_CR67","doi-asserted-by":"publisher","first-page":"882531","DOI":"10.3389\/fonc.2022.882531","volume":"12","author":"M G\u00f3mez-Llobell","year":"2022","unstructured":"G\u00f3mez-Llobell, M., Peleteiro Ra\u00edndo, A., Climent Medina, J., G\u00f3mez Centuri\u00f3n, I. & Mosquera Orgueira, A. Immune checkpoint inhibitors in acute myeloid Leukemia: A meta-analysis. Front. Oncol. 12, 882531 (2022).","journal-title":"Front. Oncol."},{"key":"76853_CR68","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.2147\/CMAR.S271442","volume":"14","author":"Y Moreno Vanegas","year":"2022","unstructured":"Moreno Vanegas, Y. & Badar, T. Clinical utility of azacitidine in the management of acute myeloid Leukemia: update on patient selection and reported outcomes. Cancer Manag. Res. 14, 3527\u20133538 (2022).","journal-title":"Cancer Manag. Res."},{"key":"76853_CR69","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1056\/NEJM199401133300204","volume":"330","author":"DL Porter","year":"1994","unstructured":"Porter, D. L., Roth, M. S., McGarigle, C., Ferrara, J. L. & Antin, J. H. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N. Engl. J. Med. 330, 100\u2013106 (1994).","journal-title":"N. Engl. J. Med."},{"key":"76853_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24876-1","volume":"12","author":"R Biavasco","year":"2021","unstructured":"Biavasco, R. et al. Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis. Nat. Commun. 12, 4559 (2021).","journal-title":"Nat. Commun."},{"key":"76853_CR71","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/s41591-022-01923-y","volume":"28","author":"S Chaib","year":"2022","unstructured":"Chaib, S., Tchkonia, T. & Kirkland, J. L. Cellular senescence and senolytics: the path to the clinic. Nat. Med. 28, 1556\u20131568 (2022).","journal-title":"Nat. Med."},{"key":"76853_CR72","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"76853_CR73","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","volume":"15","author":"D Yang","year":"2023","unstructured":"Yang, D. et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci. Transl. Med. 15, eadd1951 (2023).","journal-title":"Sci. Transl. Med."},{"key":"76853_CR74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.cmet.2020.05.002","volume":"32","author":"L Grosse","year":"2020","unstructured":"Grosse, L. et al. Defined p16High senescent cell types Are indispensable for mouse healthspan. Cell Metab. 32, 87\u201399.e6 (2020).","journal-title":"Cell Metab."},{"key":"76853_CR75","doi-asserted-by":"publisher","first-page":"15992","DOI":"10.1021\/acsnano.1c04371","volume":"15","author":"S Feola","year":"2021","unstructured":"Feola, S. et al. PeptiCHIP: A microfluidic platform for tumor antigen landscape identification. ACS Nano 15, 15992\u201316010 (2021).","journal-title":"ACS Nano"},{"key":"76853_CR76","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/978-1-4939-7537-2_14","volume":"1719","author":"M Bassani-Sternberg","year":"2018","unstructured":"Bassani-Sternberg, M. Mass spectrometry based immunopeptidomics for thediscovery of cancer neoantigens. Methods Mol. Biol. 1719, 209\u2013221 (2018).","journal-title":"Methods Mol. Biol."},{"key":"76853_CR77","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ymeth.2019.10.001","volume":"184","author":"R Noberini","year":"2020","unstructured":"Noberini, R., Restellini, C., Savoia, E. O. & Bonaldi, T. Enrichment of histones from patient samples for mass spectrometry-based analysis of post-translational modifications. Methods San Diego Calif 184, 19\u201328 (2020).","journal-title":"Methods San Diego Calif"},{"key":"76853_CR78","unstructured":"R. Noberini, T. Bonaldi, in Methods in Enzymology,(Academic Press, 2017)."},{"key":"76853_CR79","doi-asserted-by":"publisher","unstructured":"Noberini, R. et al. Spatial epi-proteomics enabled by histone post-translational modification analysis from low-abundance clinical samples. Clin. Epigenet. https:\/\/doi.org\/10.1186\/s13148-021-01120-7 (2021).","DOI":"10.1186\/s13148-021-01120-7"},{"key":"76853_CR80","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1021\/acs.jproteome.8b00133","volume":"17","author":"Z-F Yuan","year":"2018","unstructured":"Yuan, Z.-F. et al. EpiProfile 2.0: a computational platform for processing epi-proteomics mass spectrometry data. J. Proteome Res. 17, 2533\u20132541 (2018).","journal-title":"J. Proteome Res."},{"key":"76853_CR81","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nbt.2839","volume":"32","author":"JA Vizca\u00edno","year":"2014","unstructured":"Vizca\u00edno, J. A. et al. ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 32, 223\u2013226 (2014).","journal-title":"Nat. Biotechnol."},{"key":"76853_CR82","doi-asserted-by":"crossref","unstructured":"Hatice, S. K. O. et al. CUT&Tag for efficient epigenomic profiling of small samples and single cells. Nat. Commun. 10, 1930 (2019).","DOI":"10.1038\/s41467-019-09982-5"},{"key":"76853_CR83","doi-asserted-by":"crossref","unstructured":"Pinheiro, J. C. & Bates, D. M. in Mixed-Effects Models in S and S-PLUS, (Springer, New York, 2000).","DOI":"10.1007\/978-1-4419-0318-1"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76853-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76853-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:03:07Z","timestamp":1788512587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-76853-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["76853"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-76853-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9151"}}